Scottish Equity Partners (SEP) announce their investment in Dotmatics, a leading global scientific informatics software company. Dotmatic’s provide enterprise solutions for pharmaceuticals, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Their solutions include tools for knowledge management, data analysis, visualisation and storage and enterprise querying and reporting. The funding from SEP will allow Dotmatics to continue to develop innovative products and customer...
The Scottish Investment Bank have invested a record £63.5 million in to 146 Scottish Companies during 2016-2017. This is an increase of 23% from the year prior and demonstrates the SIB’s efforts to help meet the Scottish Government’s aim of increasing support to help companies raise and secure growth finance. To read the full article, click here.
NuCana, an Edinburgh-based medical firm has raised almost £75 million by floating on the stock market. NuCana develops techniques to boost the effectiveness of chemotherapy. The funds will be used to further clinical trials and expand the business in Edinburgh creating more jobs in the area. To read the full article, click here.
Leaders in gene control, Synpromics have announced their new research partnership with Solid Biosciences LLC. The partnership will focus on research around developing treatment options for Duchenne muscular dystrophy (DMD). DMD is a muscle-wasting disease that is progressive, irreversible and ultimately fatal. Currently there is no cure and unsatisfactory treatments for patients. The research aims to advance Solid Biosciences AAV muscle-directed gene therapy research programme....
Clintec opened the extension to their Glasgow headquarters where they have developed a centre of excellence for clinical research and quality assurance. The new centre has created opportunities for functional outsourcing as well as creating many new jobs in the area. To read the full article, click here.
Pharmaceutical giant GSK has unveiled its £44 million vaccine production facility in Montrose. The site, which will produce ingredients for vaccines to treat conditions such as tetanus, pneumonia and whooping cough, has been five years in the making. GSK had first announced plans for its facility, which is now being commissioned, in 2012. The facility will create a further 19 skilled jobs in Montrose by...